(Q36824929)

English

Response to chemotherapy with carboplatin plus albumin-bound paclitaxel in a patient with lymphoepithelioma-like thymic carcinoma: A case report.

scientific article published on 7 March 2016

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27123268%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Response to chemotherapy with carboplatin plus albumin-bound paclitaxel in a patient with lymphoepithelioma-like thymic carcinoma: A case report (English)

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27123268%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

lymphoepithelioma-like thymic carcinoma

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

3

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27123268%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

4

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27123268%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

author name string

Hiroshi Shima

1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27123268%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Hiroaki Ozasa

2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27123268%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Takashi Nomizo

5

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27123268%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Yoshitaka Yagi

6

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27123268%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Yuichi Sakamori

7

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27123268%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Hiroki Nagai

8

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27123268%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Sachiko Minamiguchi

9

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27123268%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Young Hak Kim

10

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27123268%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Michiaki Mishima

11

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27123268%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

language of work or name

1 reference

based on heuristic

inferred from title

publication date

7 March 2016

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27123268%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Molecular and Clinical Oncology

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27123268%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

4

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27123268%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

5

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27123268%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

715-718

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27123268%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Thymic carcinoma patients with myasthenia gravis exhibit better prognoses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4840747

29 September 2017

Response to nab-paclitaxel and nedaplatin in a heavily-metastatic thymic carcinoma: A case report

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4840747

29 September 2017

A randomized Phase III trial of weekly or 3-weekly doses of nab-paclitaxel versus weekly doses of Cremophor-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE Trial).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4840747

29 September 2017

Response to cytotoxic chemotherapy in patients previously treated with palliative-intent chemotherapy for advanced thymic carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4840747

29 September 2017

A multicenter phase II study of carboplatin and paclitaxel for advanced thymic carcinoma: WJOG4207L.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4840747

29 September 2017

nab-Paclitaxel in Combination with Carboplatin for a Previously Treated Thymic Carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4840747

29 September 2017

Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4840747

29 September 2017

Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4840747

29 September 2017

The management of thymoma: a systematic review and practice guideline

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4840747

29 September 2017

Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4840747

29 September 2017

Thymic carcinoma: state of the art review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4840747

29 September 2017

Follow-up study of thymomas with special reference to their clinical stages

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4840747

29 September 2017

Association of Epstein-Barr virus with thymic carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4840747

27 June 2018

Outcome of surgically resected thymic carcinoma: a multicenter experience.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4840747

5 September 2018

Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4840747

5 September 2018

Second-line chemotherapy of platinum compound plus CPT-11 following ADOC chemotherapy in advanced thymic carcinoma: analysis of seven cases.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4840747

5 September 2018

Weekly chemotherapy with cisplatin, vincristine, doxorubicin, and etoposide is an effective treatment for advanced thymic carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4840747

5 September 2018

Thymic carcinoma: a report of 13 cases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4840747

5 September 2018

Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4840747

4 December 2018

Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan

1 reference

https://pubmed.ncbi.nlm.nih.gov/27123268

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Salvage chemotherapy with carboplatin and paclitaxel for cisplatin-resistant thymic carcinoma--three cases

1 reference

https://pubmed.ncbi.nlm.nih.gov/27123268

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic factors of patients with thymic carcinoma after surgery: a retrospective analysis of 58 cases

1 reference

https://pubmed.ncbi.nlm.nih.gov/27123268

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Persistent and aggressive treatment for thymic carcinoma. Results of a single-institute experience with 25 patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/27123268

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of chemotherapy with carboplatin and paclitaxel for unresectable thymic carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/27123268

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chemotherapy for advanced thymic carcinoma: clinical response to cisplatin, doxorubicin, vincristine, and cyclophosphamide (ADOC chemotherapy)

1 reference

https://pubmed.ncbi.nlm.nih.gov/27123268

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Thymic carcinoma. A distinct clinical entity responsive to chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/27123268

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.3892/MCO.2016.803

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27123268%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27123268%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27123268%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36824929&oldid=2087577092"